PPIase-Parvulin Inhibitor
PPIase-Parvulin Inhibitor structure
|
Common Name | PPIase-Parvulin Inhibitor | ||
|---|---|---|---|---|
| CAS Number | 64005-90-9 | Molecular Weight | 438.38700 | |
| Density | 1.471g/cm3 | Boiling Point | 636.5ºC at 760 mmHg | |
| Molecular Formula | C22H18N2O8 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 338.7ºC | |
| Symbol |
GHS09 |
Signal Word | Warning | |
|
FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice.
EJNMMI Res. 5 , 20, (2015) Over the last decade, an increasing number of studies have been published on the use of amyloid-β (Aβ) PET imaging with different (18)F-radiopharmaceuticals for clinical characterization of Alzheimer's disease (AD) in different stages. However, distinct study... |
|
|
Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
Curr. Alzheimer Res. 12 , 563-71, (2015) Alzheimer's disease (AD) is the most common neurodegenerative disorder pathologically characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The aggregation of Aβ precedes tau pathologies in AD; however, the causal relation between the two pa... |
|
|
Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults.
J. Alzheimers Dis. 46 , 63-73, (2015) Even low levels of depressive symptoms are associated with an increased risk of cognitive decline in older adults without overt cognitive impairment (CN). Our objective was to examine whether very low, "subthreshold symptoms of depression" are associated with... |
|
|
Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease.
Brain 138 , 3089-99, (2015) Clinical Alzheimer's disease affects both cerebral hemispheres to a similar degree in clinically typical cases. However, in atypical variants like logopenic progressive aphasia, neurodegeneration often presents asymmetrically. Yet, no in vivo imaging study ha... |
|
|
Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.
Biochimie 112 , 85-95, (2015) The modest efficacy of available therapies for Hepatocellular carcinoma (HCC) indicates the need to develop novel therapeutic approaches. For the proteasome inhibitor Bortezomib (BZB), potentially attractive for HCC treatment, the mechanism of action is large... |